Back

Incidence and predictors of transthyretin cardiac amyloidosis in patients with degenerative aortic stenosis

27 August 2022 (09:15 - 10:00)
Organised by:
Congress Presentation Part of: When valvular heart disease is not alone Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Wael Jaber

Cleveland Clinic Hospital, Cleveland (United States of America)

6 More presentations in this session

Presentation thumbnail
Echocardiographic phenotype in severe aortic valve stenosis with and without cardiac amyloidosis: the AMY-TAVI trial.
Professor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Diagnostic performance of coronary CTA and CT-FFR for the detection of coronary artery disease in routine TAVI work-up
Ms J. Peper (Nieuwegein, NL)
Abstract Slides
Presentation thumbnail
Revascularization of significant coronary artery disease in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis
Mr H. Aarts (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Periprocedural outcomes of transcatheter aortic valve replacement (TAVR) in patients with and without cardiac amyloidosis-analysis from 2016-2019 national inpatient sample
Doctor S. Kambalapalli (Flint, US)
Abstract Slides
Presentation thumbnail
Adding troponin to echocardiography improves preoperative abscess detection in infective endocarditis. A REMOVE Trial analysis
Doctor M. Diab (Rotenburg An Der Fulda, DE)
Abstract Slides

Access the full session

Session thumbnail
When valvular heart disease is not alone

The Event

Event poster

ESC Congress 2022

27 August 2022 09:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources